10/26/2023 | SP | New Issue: GS Finance prices $2.08 million notes linked to basket of 109 stocks
|
10/18/2023 | BK | Ligand inks $75 million revolving credit facility via Citibank
|
2/12/2021 | CV | Market Commentary: Ligand volatile; HubSpot convertible notes soar on earnings; Twitter, Peloton improve
|
3/19/2020 | SP | New Issue: Credit Suisse sells $4.33 million contingent coupon autocallable reverse convertibles on Ligand
|
10/21/2019 | SP | New Issue: JPMorgan sells $1 million yield notes with contingent digital return on Ligand Pharmaceuticals
|
10/3/2019 | CV | Market Commentary: Broadcom active among mandatories; Tesla down, MercadoLibre underperforms; Ovid on tap
|
10/3/2019 | CV | Market Commentary: Morning Commentary: MercadoLibre convertibles underperform; Ligand, PDC Energy in trade
|
7/30/2019 | CV | Market Commentary: RingCentral, NXP Semiconductors, Neurocrine Biosciences, Ligand active post-earnings
|
5/31/2019 | SP | Goldman amends Cusip for notes tied to basket of Russell 3000 stocks
|
5/9/2019 | SP | New Issue: Goldman sells $1 million notes tied to basket of Russell 3000 stocks
|
1/17/2019 | CV | Market Commentary: Aurora Cannabis convertibles offering eyed; Energizer flat; Ligand sees slight rebound
|
1/17/2019 | CV | Market Commentary: Morning Commentary: Primary market eyes Aurora Cannabis convertible notes offering
|
1/16/2019 | CV | Market Commentary: Aurora convertibles on tap; Energizer expands on debut; EFII, Ligand notes bludgeoned
|
12/14/2018 | SP | New Issue: Credit Suisse sells $1.64 million contingent coupon reverse convertible autocalls on Ligand
|
11/8/2018 | CV | Market Commentary: Omeros convertibles on tap; Microchip in focus; Ligand improves; Horizon Global tanks
|
11/8/2018 | CV | Market Commentary: Morning Commentary: Microchip convertibles in focus post-earnings; Ligand notes improve
|
10/18/2018 | CV | Market Commentary: Evolent Health hits the market; Aegean Marine notes eyed; Ligand, Exact Sciences active
|
8/15/2018 | CV | Market Commentary: Illumina on tap; market eyes New Mountain, FTI; Enphase Energy prices; Canopy jumps
|
5/23/2018 | CV | Market Commentary: Square, Envestnet convertibles hit the market, expand; Ligand, NRG, FireEye below par
|
5/23/2018 | CV | Ligand amends 0.75% convertibles due 2019 to pay cash for conversions
|
5/22/2018 | CV | Ligand greenshoe lifts 0.75% convertibles due 2023 to $750 million
|
5/21/2018 | CV | Market Commentary: Convertibles calendar builds; Envestnet, Square on tap; market eyes FireEye, NRG Energy
|
5/18/2018 | CV | Market Commentary: Convertible issuance heavy during week; Ligand dominates trading; AmTrust loses ground
|
5/18/2018 | CV | Market Commentary: Morning Commentary: New convertible notes from Ligand in focus; AmTrust down in early trading
|
5/18/2018 | CV | New Issue: Ligand prices $650 million five-year convertible notes to yield 0.75%, up 30%
|
5/17/2018 | CV | Market Commentary: Akamai’s $1 billion deal dominates market, expands on debut; Ligand eyed; WWE improves
|
5/17/2018 | CV | Market Commentary: Morning Commentary: Akamai’s new $1 billion deal hits the market; Ligand convertibles on tap
|
5/16/2018 | CV | Ligand talks $650 million five-year convertible notes to yield 0.5% to 1%, up 27.5% to 32.5%
|
5/16/2018 | CV | Market Commentary: Akamai eyed; Ligand on tap; New Relic, Alteryx, Prospect Capital, KKR REIT hit market
|
8/18/2014 | CV | Ligand greenshoe lifts 0.75% five-year convertibles to $245 million
|
8/13/2014 | PP | Market Commentary: Convertibles weaker; Apollo drops with add-on; Ligand, EnerNOC flattish; planned AOL eyed
|
8/13/2014 | CV | Market Commentary: Convertibles weaker; Apollo drops with add-on; Ligand, EnerNOC flattish; planned AOL eyed
|
8/13/2014 | CV | Market Commentary: Morning Commentary: Four new issues debut in market; Ligand, EnerNOC trading around par
|
8/13/2014 | CV | New Issue: Ligand sells $225 million five-year convertibles at 0.75% up 35%
|
8/12/2014 | CV | Market Commentary: New Aegerion flat to better amid weak shares; Nuance bonds active after earnings, call
|
8/12/2014 | CV | Market Commentary: Morning Commentary: New Aegerion adds despite weaker shares; planned Ligand looks cheap
|
8/11/2014 | CV | Market Commentary: Tesla adds on upgrade; Chiquita edges up on takeover offer; Empire State down since issue
|
8/11/2014 | CV | Ligand plans $225 million five-year convertibles to yield 0.5%-1%, up 32.5%-37.5%
|
10/16/2013 | PP | Ligand arranges $24 million at-the-market offering of common stock
|
3/26/2012 | PP | Ligand plans $30 million at-the-market offering of common stock
|
10/14/2011 | CVPF | Ligand files $30 million shelf covering stock, debt and preferrreds
|
12/23/2008 | SS | Ligand, Pharmacopeia combine in all-stock deal
|
11/21/2008 | SS | Pharmacopeia to hold special meeting Dec. 23, offers to buy options
|
11/3/2008 | SS | Merger of Ligand Pharmaceuticals, Pharmacopeia could close in fourth quarter
|
10/30/2008 | SS | HSR wait ends early in merger of Ligand, Pharmacopeia
|
10/23/2008 | SS | El Coronado Holdings owns 4.11 million shares of Pharmacopeia
|
9/24/2008 | SS | Ligand to buy Pharmacopeia in a stock-for-stock deal that includes contingent value rights
|
3/28/2007 | SS | Third Point sells off shares of Ligand Pharmaceuticals, keeps 2.01% stake
|
3/21/2007 | SS | Ligand to pay $2.50-per-share cash dividend, authorizes $100 million stock repurchase
|
3/5/2007 | SS | Market Commentary: New Century, Fremont freefall; TXU tumbles; Palm pulls back; Pathmark, A&P higher on deal
|
11/29/2006 | CV | Ligand 6% convertible noteholders convert ahead of call
|
10/30/2006 | BTCV | Ligand calls 6% convertibles
|
9/7/2006 | BT | King Pharmaceuticals to acquire Avinza from Ligand for $265 million
|
9/7/2006 | BT | Market Commentary: New River falls over 10%; Cell Genesys loses 5% after-hours; Ligand, King up; Sinovac up 7%
|
8/2/2006 | BT | Market Commentary: Pozen pumped by partnership; Biovail battered by patent loss; Gene Logic gains on layoffs
|
8/1/2006 | BT | Ligand's president, CEO resigns
|
6/29/2006 | BT | Ligand agreement settles securities class action lawsuit for $12.15 million
|
6/12/2006 | BT | Ligand shares relisted on Nasdaq
|
5/4/2006 | BT | Ligand releases positive data on Avinza for pain reduction
|
2/14/2006 | BT | Ligand receives $2 million milestone payment from GlaxoSmithKline
|
1/17/2006 | BT | Ligand, Organon terminate Avinza co-promotion deal
|
12/15/2005 | BT | Ligand's Ontak shows 50% response rate in lymphoma study
|
12/5/2005 | BT | After bitter battle with Ligand, shareholder Third Point agrees not to put up proxy in exchange for three board seats
|
12/5/2005 | BT | Market Commentary: Noven soars on ADHD patch news; Ligand bounces on board expansion; Progenics off sharply
|
12/2/2005 | BT | Ligand, GlaxoSmithKline drug eltrombopag ups platelet count, study shows
|
11/23/2005 | BT | Market Commentary: Alexion stock dumped, credit widens; Ligand gobbled up; Epix dives on FDA news, cutbacks
|
11/18/2005 | BT | Ligand announces hiring of UBS to explore "shareholder value" options
|
11/18/2005 | BT | Market Commentary: Onyx gains after 'well-priced' deal; Elan, Biogen rise; Protein Design Labs up; Cubist higher
|
9/30/2005 | BT | Ligand stockholder Loeb demands special committee, 2 board seats, figures shares worth $17 each
|
9/26/2005 | BT | Ligand stockholder Daniel Loeb, with 9.5% stake, presses for sale of company
|
9/26/2005 | BT | Market Commentary: Eye drug names viewed in mixed fashion; Ligand gains on hopes of sale; Endo plunges on secondary
|
9/22/2005 | BT | Market Commentary: Nektar convertible at bat along with follow-ons from GTx, Renovis; Cyberonics prices wide, closes off
|
9/1/2005 | BT | Ligand Pharmaceuticals requests filing extension from Nasdaq
|
6/28/2005 | CV | Market Commentary: Lonza issue emerges; Walter better as takeover anxiety eases; Interpublic holders to get windfall payment
|
6/27/2005 | BT | Market Commentary: CV Therapeutics quiet in gray, Impax Labs refinances converts; Nitromed off; Ligand moves up
|
6/27/2005 | CV | Market Commentary: Lear eases on layoffs; airlines dive on oil spike; Weatherford watched as put nears; CV, Impax deals eyed
|
3/28/2005 | CV | Market Commentary: Nuveen deals surface; Ligand off on drug data; AIG buyers emerge; Delta lower amid deal mumbling
|
8/31/2004 | CV | Market Commentary: Six Flags higher on Gates, Redskins owner play; IMC Global rises; Albertson's off
|
8/30/2004 | CV | Market Commentary: LNR convertible leveled by $1.9 billion cash takeover; United Rentals falls on SEC inquiry
|
9/22/2003 | CV | Market Commentary: Motorola gains with stock on CEO departure; BioMarin steady after drug canceled
|
12/2/2002 | CV | Ligand says $20.25 million greenshoe exercised, raising convertibles to $155.25 million
|
11/21/2002 | CV | Market Commentary: Possible Tyco mega-deal sets market abuzz, seen placing easily; AMD, Xcel deals gain sharply
|
11/21/2002 | CV | New Issue: Ligand $135 million convertibles yield 6%, up 22%
|
11/20/2002 | CV | Market Commentary: Xcel's new deal screams higher while others edge up, languish
|
11/19/2002 | CV | Market Commentary: New issue terms, credits not so fantastic, but illustrate appetite
|
11/18/2002 | CV | Market Commentary: Trickle of new issues providing hope for eager buyers
|
11/13/2002 | CV | Ligand launches $135 million converts at 5.75%-6.25% yield, up 15-20%
|
11/13/2002 | CV | Market Commentary: Teva deal gets warm welcome in an otherwise tepid market
|
11/12/2002 | CV | Ligand Pharmaceuticals plans to sell $135 million of convertibles
|
11/12/2002 | CV | Market Commentary: New deals provide stimulation late, after very quiet session
|